JMJD1C

Across TCGA pan-cancer cohorts, JMJD1C mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of JMJD1C’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where JMJD1C mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types JMJD1C is over-expressed in tumor, although a few such as LSCC and PDAC show the opposite, repressed pattern.

HNSC, LSCC, and PDAC are the cancer types where JMJD1C tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in JMJD1C mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	IV	+0.150	.023	5	view →
LSCC	Male	III,IV	−0.161	.015	4	view →
PDAC	Male	II,III,IV	−0.186	.033	1	view →
CCRCC	Male	All	+0.108	.021	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

JMJD1C–HNSC

Open the HNSC breakdown →